Merck & Co (NYSE: MRK) → Stocks, dividends, news, and other

Merck & Co

Free disabling of ads
Dividends News
Favorites

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species, which it sells to veterinarians, distributors, and animal producers. The Healthcare Services segment offers services and solutions that focus on engagement, health analytics, and clinical services to improve the value of care delivered to patients. The Alliances segment includes results from the Company's relationship with AstraZeneca LP related to sales of Nexium and Prilosec. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

  • MRK Symbol
  • NYSE Exchange
  • 69,000 Employees
15 rated
  • $78.27, $-0.40 (-0.51%) Previous Close
  • 10,567,691 Previous Volume
  • $65.25 / $92.64 52 week low / high
  • -15.51% Percent off 52 week high
  • 2020-10-20 Updated
  • 3.12% Dividend yield (trailing)
  • 3.12% Dividend yield (forward)
  • 2,527,123,026 Public float
  • 2,529,240,000 Outstanding shares
  • 18.98 P/E
  • 198.98 B Market Cap
Free disabling of ads

Financial statements

The information is not 100% up-to-date. There may be errors or something missing. Often something is missing, there are almost no errors, but I can't rule them out. Now I'm looking for a supplier of high-quality information, but so far what I find is expensive (about $ 2000 a year).
2015 2016 2017 2018 2019
Total Revenue 39B 39B 40B 42B 47B
Cost Of Revenue 15B 13B 13B 13B 13B
Gross Profit 24B 26B 27B 29B 34B
Research and Development 6.6B 6B 9.6B 9.5B 8.9B
Selling General and Admin 10B 9.7B 9.8B 10B 11B
Operating Expense 31B 29B 32B 33B 32B
Operating Income 7.4B 10B 8B 9.8B 13B
Other Income Expense Net -2B -5.8B -1.5B -1.1B -1.8B
EBIT 7.4B 10B 8B 9.8B 13B
Interest Income 670M 690M 750M 770M 890M
Pretax Income 5.4B 4.7B 6.5B 8.7B 11B
Income Tax 940M 720M 4.1B 2.5B 1.7B
Minority Interest 17M 21M 24M -27M -66M
Net Income 4.4B 3.9B 2.4B 6.2B 9.8B
Net Income Basic 4.4B 3.9B 2.4B 6.2B 9.8B
2015 2016 2017 2018 2019
Current cash 8.5B 6.5B 6.1B 8B 9.7B
Short term investments 4.9B 7.8B 2.4B 900M 770M
Receivables 6.5B 7B 6.9B 7.1B 6.8B
Inventory 4.7B 4.9B 5.1B 5.4B 6B
Other current assets 5.1B 4.4B 4.3B 4.5B 4.3B
Current assets 30B 31B 25B 26B 27B
Long term investments 14B 12B 13B 6.9B 2.2B
Property plant equipment 13B 12B 12B 13B 16B
Goodwill 18B 18B 18B 18B 19B
Intangible assets 23B 17B 14B 11B 14B
Other assets 4.4B 4.4B 4.7B 6.3B 4.2B
Total assets 100B 95B 88B 83B 84B
Accounts payable 2.5B 2.8B 3.1B 3.3B 3.7B
Current long term debt
Other current liabilities 13B 12B 12B 12B 14B
Total current liabilities 19B 17B 19B 22B 22B
Long term debt 24B 24B 21B 20B 24B
Other liabilities 5.4B 5.6B 8.4B 9.3B 7.8B
Minority Interest 17M 21M 24M -27M -66M
Total Liabilities 57B 55B 53B 56B 58B
Common stock 2.8B 2.7B 2.7B 2.6B 2.5B
Retained earning 45B 44B 41B 43B 47B
Treasury stock 1.5M 1.3M 1.3M 1.6M 1.7M
Capital surplus 40B 40B 40B 39B 40B
Shareholder equity 45B 40B 34B 27B 26B
Net tangible assets -43B -47B -53B -60B -69B
2015 2016 2017 2018 2019
Net Income 4.4B 3.9B 2.4B 6.2B 9.8B
Depreciation 6.4B 5.4B 4.6B 4.5B 3.7B
Changes in receivables -500M 140M -200M 290M
Changes in inventories 810M 210M -150M -910M -510M
Cash change 1.1B -2B -420M 1.9B 2B
Cash flow 12B 10B 6.4B 11B 13B
Capital expenditures -1.3B -1.6B -1.9B -2.6B -3.5B
Investments 3.7B -1.3B 4.9B 7.3B 5.4B
Investing activity other
Total investing cash flows -4.8B -3.2B 2.7B 4.3B -2.6B
Dividends paid -5.1B -5.1B -5.2B -5.2B -5.7B
Net borrowings 3.5B -1.3B -1.1B 840M 1.2B
Other financing cash flows 56M -120M -200M -330M 5M
Cash flow financing -5.3B -9B -10B -13B -8.9B
Exchange rate effect -1.3B -130M 460M -210M 17M
Free disabling of ads
Free disabling of ads